FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254744897> ?p ?o ?g. }

• W4254744897 endingPage "9521" @default.
• W4254744897 startingPage "9521" @default.
• W4254744897 abstract "9521 Background: Mucosal melanoma is rare and associated with extremely poor prognosis. There was no standard treatment for advanced mucosal melanoma patients. BEAM study had demonstrated the effectivity and safety of bevacizumab combined with carboplatin plus paclitaxel in patients with previously untreated metastatic melanoma. This study was to evaluate the activity of bevacizumab combined with carboplatin plus paclitaxel in Patients with Previously Untreated Advanced Mucosal Melanoma. Methods: This study is an open-label, multicenter, randomized phase II trial. Eligible patients had metastatic, recurrent, or unresectable mucosal melanoma and no received any systemic therapy before enrollment. Patients were randomly allocated in a 2:1 ratio to receive bevacizumab (CPB arm, 5mg/kg every two weeks) or placebo (CP arm) with carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m 2 ). Treatment was continued for both groups until disease progression, unacceptable toxicity, death, or withdrawal of consent. The primary study endpoint is progress-free survival (PFS). Overall survival, disease control rate, and safety will also be assessed. Results: The first patient visit was December 1st, 2013, and the final data cutoff was August 30th, 2018. At that time, 114 patients were randomly assigned to receive CP or CPB therapy. Median PFS was 3.2 months for the CP arm and 4.7 months for the CPB arm (HR, 0.50; 95% CI, 0.33-0.72; P = 0.001). Median OS was 9.0 months in the CP arm versus 12.9 months in the CPB arm (HR, 0.61; 95% CI, 0.40-0.92; P = 0.02). The PFS was longer in the CPB arm in the subgroups of patients with neutrophil-to-lymphocyte ratio (NLR) more than 4 and patients with abnormal lactate dehydrogenase concentration (1.2 v 3.0 months, HR, 0.38; 2.0 v 4.7 months, HR, 0.39, respectively). Multivariate analysis using the Cox model showed that combination with bevacizumab was the predictor for better disease control and survival (PFS: HR 0.400, 95% CI 0.251-0.636, P < 0.001; OS: HR 0.505, 95% CI 0.313-0.814, P = 0.005). No new safety signals were observed. Conclusions: To our knowledge this is the largest study about advanced mucosal melanoma. This study demonstrated that bevacizumab in combination with carboplatin plus paclitaxel is active and safe regimen as first line treatment in patients with in advanced mucosal melanoma. A phase III study will be necessary to confirm the benefit, especially in some special setting such as elevated NLR and elevated LDH subgroups. Clinical trial information: NCT02023710." @default.
• W4254744897 created "2022-05-12" @default.
• W4254744897 creator A5000256368 @default.
• W4254744897 creator A5007348590 @default.
• W4254744897 creator A5009201250 @default.
• W4254744897 creator A5018372804 @default.
• W4254744897 creator A5033133176 @default.
• W4254744897 creator A5034855042 @default.
• W4254744897 creator A5035685296 @default.
• W4254744897 creator A5047115795 @default.
• W4254744897 creator A5064125880 @default.
• W4254744897 creator A5068116429 @default.
• W4254744897 creator A5073390793 @default.
• W4254744897 creator A5075185613 @default.
• W4254744897 creator A5078973363 @default.
• W4254744897 creator A5081138461 @default.
• W4254744897 creator A5084636770 @default.
• W4254744897 date "2019-05-20" @default.
• W4254744897 modified "2023-09-28" @default.
• W4254744897 title "A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710)." @default.
• W4254744897 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.9521" @default.
• W4254744897 hasPublicationYear "2019" @default.
• W4254744897 type Work @default.
• W4254744897 citedByCount "1" @default.
• W4254744897 countsByYear W42547448972022 @default.
• W4254744897 crossrefType "journal-article" @default.
• W4254744897 hasAuthorship W4254744897A5000256368 @default.
• W4254744897 hasAuthorship W4254744897A5007348590 @default.
• W4254744897 hasAuthorship W4254744897A5009201250 @default.
• W4254744897 hasAuthorship W4254744897A5018372804 @default.
• W4254744897 hasAuthorship W4254744897A5033133176 @default.
• W4254744897 hasAuthorship W4254744897A5034855042 @default.
• W4254744897 hasAuthorship W4254744897A5035685296 @default.
• W4254744897 hasAuthorship W4254744897A5047115795 @default.
• W4254744897 hasAuthorship W4254744897A5064125880 @default.
• W4254744897 hasAuthorship W4254744897A5068116429 @default.
• W4254744897 hasAuthorship W4254744897A5073390793 @default.
• W4254744897 hasAuthorship W4254744897A5075185613 @default.
• W4254744897 hasAuthorship W4254744897A5078973363 @default.
• W4254744897 hasAuthorship W4254744897A5081138461 @default.
• W4254744897 hasAuthorship W4254744897A5084636770 @default.
• W4254744897 hasConcept C126322002 @default.
• W4254744897 hasConcept C141071460 @default.
• W4254744897 hasConcept C142724271 @default.
• W4254744897 hasConcept C143998085 @default.
• W4254744897 hasConcept C168563851 @default.
• W4254744897 hasConcept C203092338 @default.
• W4254744897 hasConcept C204787440 @default.
• W4254744897 hasConcept C27081682 @default.
• W4254744897 hasConcept C2776694085 @default.
• W4254744897 hasConcept C2777292972 @default.
• W4254744897 hasConcept C2777658100 @default.
• W4254744897 hasConcept C2777802072 @default.
• W4254744897 hasConcept C2778239845 @default.
• W4254744897 hasConcept C2781451048 @default.
• W4254744897 hasConcept C31760486 @default.
• W4254744897 hasConcept C502942594 @default.
• W4254744897 hasConcept C71924100 @default.
• W4254744897 hasConcept C90924648 @default.
• W4254744897 hasConceptScore W4254744897C126322002 @default.
• W4254744897 hasConceptScore W4254744897C141071460 @default.
• W4254744897 hasConceptScore W4254744897C142724271 @default.
• W4254744897 hasConceptScore W4254744897C143998085 @default.
• W4254744897 hasConceptScore W4254744897C168563851 @default.
• W4254744897 hasConceptScore W4254744897C203092338 @default.
• W4254744897 hasConceptScore W4254744897C204787440 @default.
• W4254744897 hasConceptScore W4254744897C27081682 @default.
• W4254744897 hasConceptScore W4254744897C2776694085 @default.
• W4254744897 hasConceptScore W4254744897C2777292972 @default.
• W4254744897 hasConceptScore W4254744897C2777658100 @default.
• W4254744897 hasConceptScore W4254744897C2777802072 @default.
• W4254744897 hasConceptScore W4254744897C2778239845 @default.
• W4254744897 hasConceptScore W4254744897C2781451048 @default.
• W4254744897 hasConceptScore W4254744897C31760486 @default.
• W4254744897 hasConceptScore W4254744897C502942594 @default.
• W4254744897 hasConceptScore W4254744897C71924100 @default.
• W4254744897 hasConceptScore W4254744897C90924648 @default.
• W4254744897 hasIssue "15_suppl" @default.
• W4254744897 hasLocation W42547448971 @default.
• W4254744897 hasOpenAccess W4254744897 @default.
• W4254744897 hasPrimaryLocation W42547448971 @default.
• W4254744897 hasRelatedWork W2053778437 @default.
• W4254744897 hasRelatedWork W2061440113 @default.
• W4254744897 hasRelatedWork W2139697170 @default.
• W4254744897 hasRelatedWork W2395106973 @default.
• W4254744897 hasRelatedWork W2535315677 @default.
• W4254744897 hasRelatedWork W2763599771 @default.
• W4254744897 hasRelatedWork W2771290640 @default.
• W4254744897 hasRelatedWork W3163600061 @default.
• W4254744897 hasRelatedWork W4246343941 @default.
• W4254744897 hasRelatedWork W4312139687 @default.
• W4254744897 hasVolume "37" @default.
• W4254744897 isParatext "false" @default.
• W4254744897 isRetracted "false" @default.
• W4254744897 workType "article" @default.